Evidence map›Paper›PMID 39912413›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors.

Dandan Yuan, Yali Gao, Lin Xia, Han Liu, Xingye Wu, Xueyan Ding, Yudan Huang, Changchun Deng, Jin Li, Wenqi Dai and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dandan YuanSchool of Medicine, Huaqiao University, Quanzhou, China.
Yali GaoPharmacy Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Lin XiaFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
Han LiuSchool of Medicine, Huaqiao University, Quanzhou, China.
Xingye WuSchool of Medicine, Huaqiao University, Quanzhou, China.
Xueyan DingSchool of Medicine, Huaqiao University, Quanzhou, China.
Yudan HuangSchool of Medicine, Huaqiao University, Quanzhou, China.
Changchun DengSchool of Medicine, Huaqiao University, Quanzhou, China.
Jin LiSchool of Medicine, Huaqiao University, Quanzhou, China.
Wenqi DaiSchool of Medicine, Huaqiao University, Quanzhou, China.
Jieqing LiuSchool of Medicine, Huaqiao University, Quanzhou, China.
Junjie MaSchool of Medicine, Huaqiao University, Quanzhou, China.ORCID 0000-0001-5844-9984

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we firstly reported a series of biphenyl compounds bearing hydroxamic acid moiety as PD-L1/class I HDACs dual inhibitors. Among them, compound

Indexed as

Antineoplastic AgentsB7-H1 AntigenBiphenyl CompoundsDrug DiscoveryHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsB7-H1 AntigenbiphenylBiphenyl CompoundsCD274 protein, humanHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic Acidsbiphenyldual inhibitorsHDAChydroxamic acidPD-1/PD-L1

Identifiers

PMID39912413
PMCPMC11803765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.